XML 41 R30.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue Recognition (Tables)
3 Months Ended
Mar. 31, 2025
Disaggregation Of Revenue [Line Items]  
Summary of Disaggregation of Revenues
The following table disaggregates our product revenue, net by product and geographic region and disaggregates our other revenues by geographic region (in thousands):
 Three Months Ended
March 31, 2025
Three Months Ended
March 31, 2024
 U.S.Non U.S.TotalU.S.Non U.S.Total
Product revenue, net     
HEPLISAV-B$64,959 $$64,959 $46,699 $1,146 $47,845 
Total product revenue, net64,959 64,959 46,699 1,146 47,845 
Other revenue2,847 358 3,205 2,802 143 2,945 
Total revenues$67,806 $358 $68,164 $49,501 $1,289 $50,790 
HEPLISAV-B  
Disaggregation Of Revenue [Line Items]  
Schedule of Revenues from Major Customers
The following table summarizes HEPLISAV-B product revenue from each of our three largest customers (as a percentage of total HEPLISAV-B net product revenue):
 Three Months Ended
March 31,
 20252024
Largest customer31 %27 %
Second largest customer20 %19 %
Third largest customer18 %18 %
Summary of Product Revenue Allowance and Reserve Categories
The following table summarizes balances and activities in HEPLISAV-B product revenue allowance and reserve categories for the three months ended March 31, 2025 (in thousands):
 
Balance at
Beginning
of Period
Provisions
related to
current
period sales
Credit or
payments
made during
the period
Adjustments (3)
Balance
at End of
Period
Three months ended March 31, 2025:
Accounts receivable reserves (1)
$9,317 $19,695 $(19,034)$21 $9,999 
Revenue reserve accruals (2)
$31,479 $12,485 $(13,420)$(4,570)$25,974 
(1)Reserves are for chargebacks, discounts and other fees.
(2)Accruals are for returns, rebates and other fees.
(3)Adjustments for $4.6 million in connection to revenue reserve accruals primarily result from a change in estimate for product returns.
CpG 1018 adjuvant  
Disaggregation Of Revenue [Line Items]  
Summarizes balances and activities in our contract asset account The following table summarizes balances and activities in our contract asset account (in thousands):
 
Balance at
Beginning
of Period
Additions
Subtractions
Balance
at End of
Period
Three months ended March 31, 2025
Contract asset, included in other current assets (1)
$351 $2,847 $(1,613)$1,585 
Contract asset, included in other assets (long term) (2)
$71,307 $— $(10,970)$60,337 
(1)The $1.6 million of contract asset is derived from our agreement with the DoD.
(2)The Clover contract asset was included in non-current assets to reflect the timing of expected long term demand for CpG 1018 adjuvant for Clover Product. During the three months ended March 31, 2025, we recorded an allowance for doubtful accounts of approximately $11.0 million relating to the contract asset recognized for Clover. See Note 6 for further discussion.